Knight Therapeutics | GUD - Cost Of Sales


Knight Therapeutics reported CAD82.22M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Avita Medical AUD 3.3M 166K Dec/2025
Canopy Growth CAD 62.98M 9.91M Mar/2026
Cronos Group USD 24.94M 1.55M Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
IQVIA Holdings USD 3.22B 141M Jun/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Moderna USD 93M 862M Jun/2026
Omeros USD 33.16M 18.52M Jun/2024
Organigram Holdings CAD 43.39M 13.54M Mar/2026
Organon & Co USD 711M 34M Jun/2026
Revvity USD 312.82M 10.64M Jun/2026
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.3B 59.5M Jun/2026
Xeris Pharmaceuticals USD 10.57M 3.08M Mar/2026